Navigation Links
Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Date:3/26/2009

Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
2. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
3. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
4. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
5. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
6. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
7. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
8. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
9. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
10. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
11. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... TOKYO , 25 novembre 2014 Theravalues ... Super sur le marché européen au salon Hi ... Amsterdam ). Curcumine la ... une technologie amorphe (non-cristalline) à des ingrédients approuvés ... est un pigment jaune présent dans la racine ...
(Date:11/26/2014)... Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics ... of foodborne pathogens, today announced that Paul G. Thomas ... Annual Healthcare Conference on December 2, 2014 at 4:30pm ET. ... in New York, NY . ... operations, strategies and prospects may be discussed. To listen to ...
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
(Date:11/24/2014)... Calif. , Nov. 24, 2014   Veracyte, Inc. ... Bonnie H. Anderson , president and chief executive officer, will ... 26 th Annual Healthcare Conference on Tuesday, December 2, ... . The live audio webcast and subsequent ... http://investor.veracyte.com . Please connect to the website at least 15 ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2
... like Jack Welch and Larry Bossidy have been lionized ... attitude, relentless focus on bottom line performance and stellar ... run offer many valuable lessons, the management philosophies they ... for every company. Super Jacks rank and yank approach ...
... Engineering and Testing Services and Underwriters Laboratories have ... equipment building systems (NEBS) tests for telecommunications suppliers. ... such as seismic and transportation vibration, heat, humidity, ... not-for-profit product testing company, will provide customers of ...
... to be fooled by first impressions. And I have to admit ... Confoti in the January 2002 issue of DEMOletter, I was rather ... over the Internet. Dot-com businesses were imploding left and right ... site wouldn't be around for long. , ,I couldn't have been ...
Cached Biology Technology:Seven leadership lessons of Next Generation Companies 2Seven leadership lessons of Next Generation Companies 3Confoti: Revisiting a dotcom business model 2Confoti: Revisiting a dotcom business model 3Confoti: Revisiting a dotcom business model 4Confoti: Revisiting a dotcom business model 5
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/7/2014)... Auguste, associate professor, biomedical engineering, in the Grove ... New York, have identified a molecule that could ... most aggressive forms of breast cancer. , Triple ... rate owing to aggressive proliferation and metastasis and ... Auguste,s team, discovered the overexpression of intercellular adhesion ...
(Date:11/6/2014)... for a predator. Except when that predator runs so fast ... to its size, is the fastest creature on Earth. Some ... second (at about five miles per hour). The fastest human ... gold from the tiger beetle, a person would have to ... has a problem. At peak speeds, everything becomes a blur. ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3The tiger beetle: Too fast to see 2
... as earth -- and amylophagy, eating raw starches -- are ... 180 species of animals are also known to engage in ... appearing Oct. 17 in the online journal Public Library of ... Madagascar. It is one of only a few studies to ...
... of scientists searching for genes that determine the susceptibility and ... a five-year renewal grant of $4.3 million from the National ... John Reveille, M.D., of The University of Texas Health Science ... to this arthritic condition known as ankylosing spondylitis and hopes ...
... of Washington scientists have succeeded in removing the extra ... a person with Down,s syndrome. In Down syndrome, ... rather than the usual pair. A triplicate of ... trisomy. Trisomies account for almost one-quarter of pregnancy loss ...
Cached Biology News:Study documents eating of soil, raw starch in Madagascar 2Renewal grant supports genetic research into arthritis of the spine 2Extra chromosome 21 removed from Down syndrome cell line 2Extra chromosome 21 removed from Down syndrome cell line 3
... The Universal Vacuum System UVS400 is ... system. The UVS400 combines a refrigerated vapor ... in a single integrated unit. The easy-to-use, ... recovered solvent into single jar for easy ...
... FastPrep System combines 2 products into 1:, ... A molecular isolation kit , ,The ... machine and Qbiogene/BIO101 System Matrix and Isolation ... individual micro tubes eliminating the use of ...
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a ... identify recombinant plasmids. In ... and IPTG, lac ... blue, whereas recombinant colonies ...
... is a fully flexible quadrupole MS detector ... high-speed HPLC, 1-D and 2-D LC, as ... It incorporates a drying gas system to ... sensitivity, especially for low-to-medium polarity compounds, while ...
Biology Products: